Donanemab and Lecanemab rejected for the NHS

Alzheimers, Drugs, Research
20 June 202530 March 2026
by Dementia Hub

Two innovative Alzheimer’s drugs, Donanemab and Lecanemab, have been rejected by the NHS due to their exorbitant cost and limited impact. These are the first treatments to slow the disease, potentially extending

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Tags:Alzheimers Donanemab Drugs Lecanemab NICE Prof Tara Spires Jones Research Tom Dening